

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

|       |   |    |    |                        |         |
|-------|---|----|----|------------------------|---------|
| Sheet | 1 | of | 11 | Attorney Docket Number | 5517-18 |
|-------|---|----|----|------------------------|---------|

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number <sup>2</sup> (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|-----------------------------|---|---|
|                    | 1                     | 5057423                                 | 10/15/91                    | Hiserodt et al.                                 |   |
|                    | 2                     | 5308626                                 | 05/03/94                    | Landucci et al.                                 |   |
|                    | 3                     | 6090392                                 | 07/18/00                    | Berman  |   |
|                    | 4                     | 5141867                                 | 08/25/92                    | Ivanoff et al.                                  |   |
|                    | 5                     | 5814639                                 | 09/29/98                    | Liotta et al.                                   |   |
|                    | 6                     | 2002/0954542                            | 07/18/02                    | Leskovar  |   |
|                    | 7                     | 2003/0228320                            | 12/11/03                    | Ashdown   |   |
|                    | 8                     | 2005/0180971                            | 08/18/05                    | Ashdown   |   |
|                    | 9                     | 2008/0248022                            | 10/09/08                    | Ashdown   |   |
|                    | 10                    | 2009/0041760                            | 02/12/09                    | Ashdown   |   |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document Country Code <sup>3</sup> , Number <sup>4</sup> , Kind Code <sup>5</sup> (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup>  |
|--------------------|-----------------------|---|-----------------------------|---|---|---|
|                    | 11                    | DE 4120296  | 03/19/92                    | Tilgner Regina                                  |   | (translated abstract)                                   |
|                    | 12                    | EP 0374207  | 06/27/90                    | Leskovar Peter                                  |   | (Believed to correspond to WO 89/09620 provided herein) |
|                    | 13                    | EP 0358154  | 03/14/90                    | Nippon Kayaku KK                                |   |   |
|                    | 14                    | EP 0656778  | 06/14/95                    | Univ. Georgia                                   |   |   |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

|       |   |    |    | <b>Complete if Known</b> |                        |
|-------|---|----|----|--------------------------|------------------------|
|       |   |    |    | Application Number       | 10/576,981             |
|       |   |    |    | Filing Date              | March 2, 2007          |
|       |   |    |    | First Named Inventor     | Martin Leonard Ashdown |
|       |   |    |    | Art Unit                 | 1648                   |
|       |   |    |    | Examiner Name            | Zachariah Lucas        |
| Sheet | 2 | of | 11 | Attorney Docket Number   | 5517-18                |

|    |                |          |                                |                       |  |
|----|----------------|----------|--------------------------------|-----------------------|--|
| 15 | EP 0736533     | 10/09/96 | Sqibb Bristol Myers Co         |                       |  |
| 16 | WO 02/45735    | 06/13/02 | Univ Technologies Int. et al.  |                       |  |
| 17 | WO 06/026821   | 03/16/06 | Immunaid Pty Ltd. et al.       |                       |  |
| 18 | WO 1995/19183  | 09/30/95 | Univ Massachusetts Medical     |                       |  |
| 19 | WO 1995/20660  | 08/03/95 | Univ Massachusetts Medical     |                       |  |
| 20 | WO 2005/034995 | 04/21/05 | Chiron Corp                    |                       |  |
| 21 | WO 2005/040816 | 05/06/05 | Immunaid Pty Ltd               |                       |  |
| 22 | WO 2005/070090 | 08/04/05 | Univ California                |                       |  |
| 23 | WO 2005/072777 | 08/11/05 | Curix Aps                      |                       |  |
| 24 | WO 89/09620    | 10/19/89 | Leskovar Peter                 | (translated abstract) |  |
| 25 | WO 90/07119    | 06/28/90 | Immunodiagnostics Inc          |                       |  |
| 26 | WO 91/09872    | 07/11/91 | Univax Biolog Inc              |                       |  |
| 27 | WO 92/22654    | 12/23/92 | Microgenesys Inc               |                       |  |
| 28 | WO 96/30025    | 10/03/96 | The Welcome Foundation Limited |                       |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

3

of

11

| <b>Complete if Known</b> |                        |
|--------------------------|------------------------|
| Application Number       | 10/576,981             |
| Filing Date              | March 2, 2007          |
| First Named Inventor     | Martin Leonard Ashdown |
| Art Unit                 | 1648                   |
| Examiner Name            | Zachariah Lucas        |

Attorney Docket Number

5517-18

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

| Examiner Initials* | Cite No. <sup>1</sup> |  |
|--------------------|-----------------------|--|
|                    | 29                    | ABC Online, "AM- Cells Switched off for tumour treatment", March 12, 2009, <a href="http://www.abc.net.au/am/content/2008/s2513799.htm">http://www.abc.net.au/am/content/2008/s2513799.htm</a> , accessed April 5, 2009  |
|                    | 30                    | Annunziato, et al., "Phenotype, Localization, and Mechanism of Suppression of CD4+ CD25+ Human Thymocytes," The Journal of Experimental Medicine, vol. 196, no. 3, pp. 379-387, August 5, 2002   |
|                    | 31                    | Babbe, et al., "Clonal Expansions of CD8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction," The Journal of Experimental Medicine, vol. 192, no. 3, pp. 393-404, August 7, 2000 |
|                    | 32                    | BARIN, F. et al.; Virus Envelope Protein of HTL V-III Represents Major Target Antigen for Antibodies in AIDS Patients; May 31, 1985; pp. 1094-1096; V. 228; Science; Gale Group Information Integrity  |
|                    | 33                    | BATAILLE, R.. et al., -Cytokines and lymphoplasmocytic proliferations: essential role or interleukin 6. xp. 002351766. February 1. 1993. La Revue du praticien. Vol. 43. No.3. pgs 275-278.  |
|                    | 34                    | Beilharz et al., "Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression" J Immunol 2004, 172:4917-4925   |
|                    | 35                    | BEILHARZ et al., "Prevention of Murine AIDS by timed immune regulator cell ablation", Journal of Interferon and Cytokine Research, vol. 22, no. suppl. 1, October 2002, pages S-177  |
|                    | 36                    | Belkaid et al., "Natural regulatory T cells in infectious disease" Nature Immunol 2005, 6(4):353-360   |
|                    | 37                    | BERD, D "Effect of Low Dose Cyclophosphamide on the Immune System of Cancer Patients: Reduction of T- Suppressor Function without Depletion of the C08+ Subset." XP-002351767 Cancer Research. Vol. 47. Issue 12, June 15, 1987.   |
|                    | 38                    | Beyer et al., "Regulatory T cells in cancer" Blood 2006, 108(3)804-811   |
|                    | 39                    | Brandi et al., "Effect of antiviral treatments on the bone marrow in murine AIDS" Blood Cells, Molecules and Diseases 1995, 21 (12)109-118   |
|                    | 40                    | Bretz, et al., "Inflammatory Cytokine Regulation of Fas-mediated Apoptosis in Thyroid Follicular Cells." The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25433-25438, September 3, 1999   |
|                    | 41                    | Bruzzone, et al., "Temporal Patterns of C-Reactive Proteins and Other Acute Phase Proteins After Kidney Transplantation," Transplantation Proceedings, vol. XIX, no. 5, pp. 3727-3730, October 1987  |

|                    |  |                 |
|--------------------|--|-----------------|
| Examiner Signature |  | Date Considered |
|--------------------|--|-----------------|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

4

of

11

| <i><b>Complete if Known</b></i> |                        |
|---------------------------------|------------------------|
| Application Number              | 10/576,981             |
| Filing Date                     | March 2, 2007          |
| First Named Inventor            | Martin Leonard Ashdown |
| Art Unit                        | 1648                   |
| Examiner Name                   | Zachariah Lucas        |
| Attorney Docket Number          | 5517-18                |

|    |   |
|----|---|
| 42 | Carcelain G. et al. "Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy". <i>Curr Opin Immunol.</i> 2001 Aug; 13(4):483-8.   |
| 43 | CARINI et al. (1994) AIDS Res. Hum. Retroviruses 10:121-130   |
| 44 | CHATTOPADHYAY, SISIR K. et al.; Structure of Endogenous Murine Leukemia Virus DNA in Mouse Genomes; October. 1980. pp. 5774-5778; V. 77. No. 10; Proc. Natl. Acad. Sci. USA; Biochemistry   |
| 45 | Cho, et al., "Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling," <i>Clinical Cancer Research</i> , vol. 10, pp. 43-52, January 1, 2004  |
| 46 | COLL, J. et al.; Antibodies to Human Immunodeficiency Virus (HIV-1) in Autoimmune Diseases: Primary Sjogren's Syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis and Autoimmune Thyroid Diseases; December 21.1995; DD. 451-457; V. 14. No.4; <i>Clinical Rheumatology</i>        |
| 47 | Cunningham RK et al. "Murine AIDS: a model for the human disease or a distinct entity?" <i>Immunol Res.</i> Vol. 13(1994), pp 21-28.  |
| 48 | DENNEHY, PENELOPE H; Active Immunization in the United States: Developments over the Past Decade, <i>Clinical Microbiology Reviews</i> ; October. 2001; pp. 872-908; V. 14. No.4; American Society for Microbiology   |
| 49 | Dias et al., "Animal models used for the evaluation of antiretroviral therapies" in <i>Current HIV Research</i> 2006, 4(4):431-446, Abstract only. On the world wide web at <a href="http://www.bentham.org/chivr/contabs/chiv4-4.htm">http://www.bentham.org/chivr/contabs/chiv4-4.htm</a> |
| 50 | Dittmer et al., "Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection" <i>Immunity</i> 2004, 20:293-303   |
| 51 | Elliott, et al., "Suppression of Fever and the Acute-Phase Response in a Patient with Juvenile Chronic Arthritis Treated with Monoclonal Antibody to Tumour Necrosis Factor-x (cA2)," <i>British Journal of Rheumatology</i> , vol. 36, no. 5, pp. 589-593, 1997                            |
| 52 | Errante D. et al. "Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF". <i>Ann Oncol.</i> 1999 Feb; 10(2): 189-95.                  |
| 53 | Fratemale et al., "Repeated cycles of alternate administration of fludarabine and zidovudine plus didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels" <i>Virology</i> 2002, 302:354-362   |
| 54 | Freed, et al., "Early Detection of Renal Allograft Rejection by Serial Monitoring of Serum C-Reactive Protein," <i>Transplantation</i> , vol. 37, no. 2, pp. 215-218, February 1984   |
| 55 | Fu, et al., "CD4+ CD62+ T-Regulatory Cell Subset Has Optimal Suppressive and Proliferative Potential," <i>American Journal of Transplantation</i> , vol. 4, no. 1, pp. 65-78, January 2004  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

|       |   |    |    | <i>Complete if Known</i>                    |
|-------|---|----|----|---|
| Sheet | 5 | of | 11 | Application Number 10/576,981               |
|       |   |    |    | Filing Date March 2, 2007                   |
|       |   |    |    | First Named Inventor Martin Leonard Ashdown |
|       |   |    |    | Art Unit 1648                               |
|       |   |    |    | Examiner Name Zachariah Lucas               |
|       |   |    |    | Attorney Docket Number 5517-18              |

|    |   |
|----|---|
| 56 | FUJITA et al., "The Value of Acute-Phase Protein Measurements After Curative Gastric Cancer Surgery", Arch. Surg. 1999, 134: 73-75  |
| 57 | Gaur et al., "Role of a cytotoxic- T-lymphocyte epitope-defined, alternative gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome" J Virol 2005, 79(7):4308-4315   |
| 58 | GAVIN, MARC A. et al., Homeostasis and Anergy of CD4+CD25+ Suppressor T Cells In Vivo; December 10, 2001; pp. 33-41; V. 3, No.1; Howard Hughes Medical Institute, University of WaShington; Nature Publishing Group <a href="http://immunol.nature.com">http://immunol.nature.com</a> |
| 59 | Gelinas, et al., "Immunotherapy for Alzheimer's disease," Proceedings of the National Academy of Sciences of the United States of Armerica, vol. 101, no. 2, pp. 14657-14662, October 5,2004  |
| 60 | GEORGE et al., "Immunokinetics of Autoreactive CD4 T Cells in Blood: A Reporter for the "Hit-and-Run" Autoimmune Attack on Pancreas and Diabetes Progression", Journal of Autoimmunity vol. 23 (2004) pp. 151-160   |
| 61 | GHYKA G et al. "An Experimental Model Comparing the Antineoplastic and the Immunosuppressive Effects of some Cytostatics: XP-02351730 Archives roumaines de pathologie experimentale et de microbiologie. Romania 1989 Jan-March  |
| 62 | GORDON, A. et al., "Cisplatin Vinblastine and Bleomycin Combination Therapy In Resistant Gestational IB.F./4 Trophoblastic Disease," XP-002351699 Cancer. vol. 56. No.7. 1986 pgs 1407-1410   |
| 63 | Goverman, "Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein." Immunological Reviews, vol. 169, no. 1, pp. 147-159, June 1999   |
| 64 | HAMAJIMA et al. (1997) Clin. Immunol. Immunopathol. 83:179-184  |
| 65 | HARTLEY, JANET W. et al.; Retrovirus-Induced Murine Acquired Immunodeficiency Syndrome: Natural History of Infection and Differing Susceptibility ofinbred Mouse Strains; March, 1989; pp. 1223-1231; Vol. 63, No.3; Journal of Virology; American Society for Microbiology           |
| 66 | Herniou et al., "Retroviral diversity and distribution in vertebrates" J Virol 1998, 72(7):5955-5966  |
| 67 | Hill, et al., "Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines," Blood, vol. 90, no. 8, pp. 3204-3213, October 15, 1997  |
| 68 | HIROAKI MITSUYA et al.; Targeted Therapy of Human Immunodeficiency Virus-Related Disease; July. 1991; 52 pp. 2369-2381; V. 5; The FASEB Journal   |
| 69 | HIURA, et al., "Both Regulatory T Cells and Antitumor Effector T Cells are primed in the same draining lymph nodes during tumor progression", Journal of Immunology, 2005, pp. 5058-5066  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 6 of 11

### *Complete if Known*

|                      |                        |
|----------------------|------------------------|
| Application Number   | 10/576,981             |
| Filing Date          | March 2, 2007          |
| First Named Inventor | Martin Leonard Ashdown |
| Art Unit             | 1648                   |
| Examiner Name        | Zachariah Lucas        |

Attorney Docket Number 5517-18

|    |  |
|----|--|
| 70 | HOLCOMBE et al., "The Immunosuppressive Agent 15-Deoxyspergualin Functions by Inhibiting Cell Cycle Progression and Cytokine Production Following Naive T Cell Activation", Journal of Immunology, vol. 169, no. 9, pp. 4982-4989, 2002  |
| 71 | HRYNIEWICZ et al., "CTLA-4 blockage decreases TGF-B, IDO, and viral RNA expression in tissues of SIV mac251-infected macaques", Blood, vol. 108, no. 12, December 1, 2006  |
| 72 | IMAMI et al. (1999) Clin. Exp. Immunol. 118: 78-86   |
| 73 | IMAMI et al., "Development of immunotherapeutic strategies for HIV-1", Expert Opinion, vol. 1, no. 5, September 2001, pp. 803-816  |
| 74 | Iwashiro et al., "Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection" PNAS 2001, 98( 16): 9226-9230  |
| 75 | Jonuleit, et al., "Identification and Functional Characterization of Human CD4+ CD25+ T Cells with Regulatory Properties Isolated from Peripheral Blood," The Journal of Experimental Medicine, vol. 193, no. 11, pp. 1285-1294, June 4, 2001  |
| 76 | KANAI et al. (1996) J. Immunol. 157:3681-3687  |
| 77 | Keimowitz, "Dementia Improvement With Cytotoxic Chemotherapy: A Case of Alzheimer Disease and Multiple Myeloma," Archives of Neurology, vol. 54, no. 4, pp. 485-488, April 1997  |
| 78 | KILBY, J. MICHAEL MD et al.; Recurrence of the Acute HIV Syndrome After Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report; September 19, 2000; pp. 435-438; V. 133(6); Annals of Internal Medicine; American College of Physicians   |
| 79 | KINTER et al., "CD25+ CD4+ Regulatory T Cells from the Peripheral Blood of Asymptomatic HIV-infected individuals Regulate CD4+ and CD8+ HIV-specific T Cell Immune Responses in vitro and are associate with favorable clinical markers of disease status", Journal of Experimental Medicine, vol. 200, no. 3, pp. 331-343, August 2, 2004 |
| 80 | KINTER et al., "Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected Individuals", PNAS, vol. 104, no. 9, pp. 3390-3395, February 27, 2007   |
| 81 | KNOECHEL et al., "Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen", JEM, vol. 202, November 21, 2005, 12 pages  |
| 82 | Kohm, et al., "CD4+ CD25+ Regulatory T Cells Suppress Antigen-Specific Autoreactive Immune Responses and Central Nervous System Inflammation During Active Experimental Autoimmune Encephalomyelitis," The Journal of Immunology, vol 169, no. 9, pp. 4712-4716, November 1, 2002  |
| 83 | Kukreja, et al., "Autoimmunity and Diabetes," The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 12, pp. 4371-4378, December 1999  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet      7      of      11

***Complete if Known***

|                      |                        |
|----------------------|------------------------|
| Application Number   | 10/576,981             |
| Filing Date          | March 2, 2007          |
| First Named Inventor | Martin Leonard Ashdown |
| Art Unit             | 1648                   |
| Examiner Name        | Zachariah Lucas        |

Attorney Docket Number      5517-18

|    |   |
|----|---|
| 84 | Liang et al., "Murine AIDS, a key to understanding retrovirus-induced immunodeficiency"<br>Viral Immunol 1996, 9 (4):225-239; Abstract only. PMID: 8978019; PubMed, Indexed for MEDLINE   |
| 85 | LIFSON, JEFFREY D. et al.; Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment; March. 2000; DP. 2584-2593; V. 74. No.6; Journal of virology: American Society of Microbiology |
| 86 | LIM et al., "Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy", Immunology and Cell Biology, 2006, 84, 530-536   |
| 87 | LIM et al., "Proportions of circulating T cells with a regulatory cells phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy," AIDS 2007, vol. 21, pp. 1525-1534  |
| 88 | LORI et al., "Hydroxyurea and HIV: 5 years later -- from antiviral to immune-modulating effects", AIDS (London, England) 20 Aug. 1999, vol. 13, no. 12, pp. 1433-1442   |
| 89 | LORI et al., "Targeting HIV Reservoirs and reconstituting the immune system", AIDS research and human Retroviruses, vvol. 15, no. 18, 1999, pp. 1597-1617   |
| 90 | MAHMOUD et al., "The Role of C-Reactive Protein as a Prognostic Indicator in Advanced Cancer," Current Oncology Reports 2002 4:250-255.   |
| 91 | MASON et al., "Expression of Norwalk Virus Capsid Protein in Transgenic Tobacco and Potato and its Oral Immunogenicity in Mice," Proc. Natl. Acad. Sci. USA, Vol. 93, pp 5335-5340, May 1996.   |
| 92 | Maury, et al., "Comparative study of serum amyloid-related protein SAA, C-reactive protein, and B2-microglobulin as markers of renal allograft rejection," Clinical Nephrology, vol. 22, no. 6, pp. 284-292, date unknown   |
| 93 | MCGUIRK, PETER et al.; Pathogen-Specific Regulatory T Cells Provoke a Shift in the Th1/Th2 Paradigm in Immunity to Infectious Diseases; September, 2002; pp. 450-455; V. 23 No.9; TRENDS in Immunology; Elsevier Science Ltd  |
| 94 | MCMILLAN et al. Disease of the Colon & Rectum 1997; 40: 1068-1071   |
| 95 | MCMILLAN et al. The American Journal of Surgery 1995, 170:319-322   |
| 96 | Medline Abstract Accession No. PMID 10228499; AVERSA, S.M., et al.; Tumori; Jan.-Feb. 1999, 85(1), 54-59.   |
| 97 | Medline Abstract Accession No. PMID 10950369; DEZUBE, B.J.; Semin Oneal; August 2000, 27(4), 424-430.   |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 8 of 11

### *Complete if Known*

|                      |                        |
|----------------------|------------------------|
| Application Number   | 10/576,981             |
| Filing Date          | March 2, 2007          |
| First Named Inventor | Martin Leonard Ashdown |
| Art Unit             | 1648                   |
| Examiner Name        | Zachariah Lucas        |

|  |     |  |
|--|-----|--|
|  | 98  | Medline Abstract Accession No. PMID 8959247; ZANUSSI, S., et al.; AIDS Res Hum Retroviruses; December 10, 1996; 12(18), 1703-1707.   |
|  | 99  | MEDSTRAND et al., "Characterization of Novel Reverse transcriptase encoding human endogenous retroviral sequences similar to type A and type B retroviruses: Differential transcription in normal human tissues", Journal of Virology, Nov. 1993, vol. 67, no. 11, pp. 6778-6787 |
|  | 100 | MEHIGAN et al. Changes in T cell subsets, interleukin-6, and C-reactive protein after laparoscopic and open colorectal resection for malignancy". Surg. Endosc. 2001; 15:1289-1293   |
|  | 101 | Miller et al., "Human immunodeficiency virus and AIDS: insights from animal lentiviruses" J Virol 2000, 74 D (16):7187-7195  |
|  | 102 | MIYAZONO et al. "Surgical Maneuvers Enhance Molecular Detection of Circulating Tumor Cells During Gastric Cancer Surgery", Annals of Surgery 2001, 233: 189-194  |
|  | 103 | Monsonego, et al., "Immunotherapeutic Approaches to Alzheimer's Disease," Science, vol. 302, pp. 834-838, October 31, 2003   |
|  | 104 | MOORE, JOHN P. et al.; MINIREVIEW Genetic Subtypes. Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development; July, 2001; pp. 5721-5729; V. 75, No. 13; Journal of Virology; American Society for Microbiology  |
|  | 105 | Morgan, et al., "CD25+ Cell Depletion Hastens the Onset of Severe Disease in Collagen-Induced Arthritis," Arthritis & Rheumatism, vol. 48, no. 5, pp. 1452-1460, May 2000  |
|  | 106 | MORSE et al., "Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS", AIDS, 1992, vol. 6, pp. 607-621   |
|  | 107 | MORTENSEN, "C-Reactive Protein, Inflammation, and Innate Immunity", Immunologic Research, 2001, vol. 24, no. 2, pp. 163-176  |
|  | 108 | Murphy, et al., "New strategies for preventing graft-versus-host disease," Current Opinion in Immunology, vol. 11, no. 5, pp. 509-515, October 1, 1999   |
|  | 109 | Nasti et al. "A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma" Drug Safety, 1999 May; 20(5):403-425   |
|  | 110 | Orenstein R "Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection" Pharmacotherapy Vol. 22(2002) pp1468-78.  |
|  | 111 | ORTIZ, GABRIEL M. et al.; HIV-1-Specific Immune Responses in Subjects Who Temporarily Contain Virus Replication After Discontinuation of Highly Active Antiretroviral Therapy, August 16, 1999; V. 0, No. 1999; J. Clin Invest.; American Society for Clinical Investigation     |
|  | 112 | Pepys, et al., "C-reactive protein: a critical update," The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805-1812, June 2003  |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

*Complete if Known*

|                      |                        |
|----------------------|------------------------|
| Application Number   | 10/576,981             |
| Filing Date          | March 2, 2007          |
| First Named Inventor | Martin Leonard Ashdown |
| Art Unit             | 1648                   |
| Examiner Name        | Zachariah Lucas        |

Sheet

9

of

11

Attorney Docket Number

5517-18

|     |   |
|-----|---|
| 113 | RACKE et al., "Intravenous Antigen Administration as a Therapy for Autoimmune Demyelinating Disease", Annals of Neurology, vol. 39, no. 1, pp. 46-56, 1996  |
| 114 | RAKOWICZ-SZULCZYNSKA, EVA M. et al.; Human Immunodeficiency Virus Type 1-Like DNA Sequences and Immunoreactive Viral Particles with Unique Association with Breast Cancer; September, 1998; pp. 645-653; V. 5, No.5; Clinical and Diagnostic Laboratory Immunology; American Society for Microbiology |
| 115 | RAKOWICZ-SZULCZYNSKA, EVA M.; Relevance of the Viral RAK Alpha Gene in Diagnosis of Malignant Versus Nonmalignant Tumors of the Ovary and Uterus; May, 2000; pp. 360-365; V. 7, No.3; Clinical and Diagnostic Laboratory Immunology; American Society for Microbiology                                |
| 116 | Read et al., "CD4+ regulatory T cells" Curr Opin Immunol 2001, 13:644-649   |
| 117 | Rossi et al., "Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphonomethoxypropyl)adenine" J Antimicrobial Chemo 2002;50:639   |
| 118 | Rouse et al., "Regulatory T Cells in virus infections" Immunol Rev 2006, 212:272-286  |
| 119 | SAHNI et al., "HIV Vaccine Strategies - an Update," Armed Forces Medical College, Vol. 60, No. 2, 2004, pages 157-164   |
| 120 | Sakaguchi et al., "Regulatory T cells: key controllers of immunologic self-tolerance" Cell 2000, 101:455-458  |
| 121 | Santamaria, "Effector lymphocytes in autoimmunity," Current Opinion in Immunology, vol. 13, no. 6, pp. 663-669, December 1, 2001  |
| 122 | Shepherd FA et al. "Combination chemotherapy and a-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome" CMAJ 139 (1988):635-639.  |
| 123 | SHIH et al., "Detection of Multiple, Novel Reverse Transcriptase Coding Sequences in Human Nuclei Acids: Relation to Primate Retroviruses," Journal of Virology, Jan 1989, vol. 63, no. 1, pp 64-75   |
| 124 | Smith, et al., "Use of Two-Dimensional Gel Electrophoresis to Measure Changes in Synovial Fluid Proteins from Patients with Rheumatoid Arthritis Treated with Antibody to CD4," Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 1, pp. 105-111, January 2001                               |
| 125 | Speiser, et al., "TNF Receptor p55 Controls Early Acute Graft-Versus-Host Disease," The Journal of Immunology, vol. 158, no. 11, pp. 5185-5190, June 1, 1997  |
| 126 | STOTT, J. et al.; Candidate Vaccines Protect Macaques Against Primate Immunodeficiency Viruses; 1998; pp. S-265-S-270; V. 14. Suppl. 3; Aids Research and Human Retroviruses; Mary Ann Liebert, Inc.  |

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

10

of

11

***Complete if Known***

|                      |                        |
|----------------------|------------------------|
| Application Number   | 10/576,981             |
| Filing Date          | March 2, 2007          |
| First Named Inventor | Martin Leonard Ashdown |
| Art Unit             | 1648                   |
| Examiner Name        | Zachariah Lucas        |

|  |  |  |  |                        |         |
|--|--|--|--|------------------------|---------|
|  |  |  |  | Attorney Docket Number | 5517-18 |
|--|--|--|--|------------------------|---------|

|     |  |
|-----|--|
| 127 | Suri-Payer, et al., "CD4+CD25+ T Cells Inhibit Both the Induction and Effector Function of Auto-reactive T Cells and Represent a Unique Lineage of Immunoregulatory Cells," <i>The Journal of Immunology</i> , vol. 160, pp. 1212-1218, D February 1998  |
| 128 | TAKAHASHI, TAKESHI; Immunologic Self- Tolerance Maintained by CD20 CD4' Naturally Anergic and Suppressive T Cells: Induction of Autoimmune Disease by Breaking Their Anergic/Suppressive State; September 10, 1998; DO. 1969-1980; V. 10, No. 12; <i>International Immunology; Japanese Society for Immunology</i> |
| 129 | TAN et al., "Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase" <i>Journal of Natural Products</i> , vol. 54, no. 1, 1991, pages 143-154   |
| 130 | TAWA, A. et al., "Rhabdomyosarcoma of the Urinary Bladder. Complete remission induced by Vinblastine, cis- platinum, and Bleomycin" XP, o02351700 Gan to Kagaku Ryoho Japan. December 1982   |
| 131 | TONIATTI, C., et al., Regulation of the Human C-Reactive Protein Gene A Major Marker of Inflammation and Cancer." XP-002351697. 1990. <i>Molecular Biology and Medicine</i> . Vol. 7. No.3. 1990. pgs 199-212  |
| 132 | VAHLENKAMP et al., "Feline Immunodeficiency Virus infection phenotypically and functionally activates immunosuppressive CD4+CD25+ T Regulatory Cells", <i>Journal of Immunology</i> , 2003, pp. 4752-4761  |
| 133 | VAHLENKAMP et al., "The role of CD4+ CD25+ regulatory T cells in viral infections", <i>Veterinary immunology and Immunopathology</i> , vol. 108, pp. 219-225, 2005   |
| 134 | Verma, et al., "Role of MHC class I expression and CD8+ T cells in the evolution of iodine-induced thyroiditis in NOD- H2h4 and NOD mice," <i>European Journal of Immunology</i> , vol. 30, pp. 1191-1202, 2000  |
| 135 | WANG et al., "Detection of Mammary Tumor Virus ENV Gene-like Sequences in Human Breast Cancer", <i>Cancer Research</i> 55, 5173-5179, November 15, 1995  |
| 136 | Wong et al., "Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cdna library," <i>Nature Medicine</i> , vol. 5, no. 9, pp. 1026-1031, September 17, 2002   |
| 137 | Wu, et al., "Tumor necrosis factor-x regulation of CD4+ CD25+ T cell levels in NOD mice." <i>Proceedings of the National Academy of Sciences</i> , vol. 99, no. 19, pp. 12287-12292, September 17, 2002  |
| 138 | Yoon, et al., "Cellular and Molecular Pathogenic Mechanisms of Insulin-Dependent Diabetes Mellitus," <i>Health Aging for Functional Longevity: Molecular and Cellular Interactions in Senescence, Annals of The New York Academy of Sciences</i> , vol. 928, pp. 200-211, April 2001                               |
| 139 | ZOU et al. (1999) J. Acquir. Immune Defic. Syndr. 22:31-38   |
| 140 | PATENT COOPERATION TREATY, PCT International Search Report, dated 11/14/05, 4 pages  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

|  |    |    |    |                          |                        |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449A/PTO                            |    |    |    | <i>Complete if Known</i> |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b> |    |    |    | Application Number       | 10/576,981             |
|  |    |    |    | Filing Date              | March 2, 2007          |
|  |    |    |    | First Named Inventor     | Martin Leonard Ashdown |
|  |    |    |    | Art Unit                 | 1648                   |
|  |    |    |    | Examiner Name            | Zachariah Lucas        |
| Sheet  | 11 | of | 11 | Attorney Docket Number   | 5517-18                |

|     |   |
|-----|---|
| 141 | International Search Report for International (PCT) Application No. PCT/AU2004/001456, mailed December 8, 2004                            |
| 142 | International Preliminary Report on Patentability for International (PCT) Application No. PCT/AU2004/001456, completed September 27, 2005 |
| 143 | Written Opinion for International (PCT) Patent Application No. PCT/AU2004/001456, mailed December 8, 2004                                 |
| 144 | Supplementary European Search Report for EP 03 70 1355, complete December 5, 2005   |
| 145 | SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT, dated 8/8/08, 8 pages   |
| 146 | European Examination Report, dated July 9, 2008, 10 pages   |
| 147 | European Supplementary Search Report, dated August 6, 2008, 6 pages   |

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Zachariah Lucas/ | Date Considered | 05/27/2010 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./